About the Company
We do not have any company description for Aura Biosciences, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Aura Biosciences, Inc.
Aura Biosciences Reports Q2 Results and $75M Financing
Aura Biosciences Inc ( ($AURA) ) just unveiled an announcement. On August 13, 2025, Aura Biosciences reported its second-quarter financial results ...
Aura Biosciences Advances Clinical Trials and Strengthens Finances
Aura Biosciences Inc ( ($AURA) ) has released its Q2 earnings. Here is a breakdown of the information Aura Biosciences Inc presented to its ...
AURA Stock Quote Price and Forecast | CNN
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells ...
Aura Biosciences, Inc.: Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 ...
Aura Biosciences, Inc. (NASDAQ:AURA) Shares Purchased by Wells Fargo ...
Aura Biosciences, Inc. has a 52 week low of $4.84 and a 52 week high of $12.38. Aura Biosciences (NASDAQ:AURA – Get Free Report) last released its earnings results on Monday, March 24th.
Wall Street Analysts Believe Aura Biosciences, Inc. (AURA ... - Nasdaq
Aura Biosciences, Inc. (AURA) closed the last trading session at $7.98, gaining 1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Aura Biosciences Reports Second Quarter 2023 Financial Results and ...
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications.
Aura Biosciences to Participate in Upcoming Investor Conferences
--Aura Biosciences, Inc., a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior ...
Aura Biosciences Inc (AURA) Receives a Buy from Scotiabank
Based on Aura Biosciences Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.34 million. In comparison, last year the company had ...
Aura Biosciences Inc. Research & Ratings | AURA | Barron's
Aura Biosciences Inc. research and ratings by Barron's. View AURA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
Aura Biosciences Inc AURA - Morningstar
Aura Biosciences Inc AURA Stock XNAS Rating as of Jun 20, 2025 Download PDF Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends ...
Evercore ISI Remains a Buy on Aura Biosciences Inc (AURA)
Based on Aura Biosciences Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.34 million. In comparison, last year the company had ...
Similar Companies
Loading the latest forecasts...